



**July 27, 2018**

**UPS EXPRESS MAIL**

To the Registrant of [www.stdrapidtest.com](http://www.stdrapidtest.com)  
c/o LT Labs LLP  
10 Anson Road #26-04  
International Plaza  
Singapore 079903

To Whom It May Concern:

The Office of Compliance and Biologics Quality in the Center for Biologics Evaluation and Research of the United States Food and Drug Administration (FDA) has reviewed your Internet website <http://www.stdrapidtest.com>. Your website promotes the iCare HIV 1&2 Rapid Screen Test and the iCare HIV 1&2 Oral Swab Rapid Screen Test. Copies of the pertinent Internet website pages are enclosed for your reference.

HIV test kits are medical devices within the meaning of section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act) because they are in vitro diagnostic instruments intended for use in the diagnosis of disease. Under section 513(f) of the Act, the devices are class III devices, which under section 501(f)(1)(B) are deemed to be adulterated unless they have received premarket approval under section 515 or an investigational device exemption (IDE) under section 520(g). These statutory provisions protect the public health and help ensure that new medical devices are safe and effective.

The devices promoted on your Internet website are not approved for sale in the United States and have not received investigational device exemptions from premarket approval. The Internet website above does not exclude the sale of the HIV test kits in the United States. Instead, your website appears to promote the iCare HIV 1&2 Rapid Screen Test and the iCare HIV 1&2 Oral Swab Rapid Screen Test to buyers in the United States. For example, your website sells the devices in U.S. dollars. Moreover, the United States is included in the "drop-down" box on the payment page, inviting orders for shipment of the products to the United States.

The introduction, or delivery for introduction, of the iCare HIV 1&2 Rapid Screen Test and the iCare HIV 1&2 Oral Swab Rapid Screen Test into interstate commerce in the United States would be violative under sections 301(a) and 501(f)(1)(B) of the Act.

Additionally, product labeling that is false or misleading in any particular renders a device misbranded under section 502(a) of the Act. If you introduce, or deliver for introduction, a misbranded device into interstate commerce in the United States, you would be doing so in violation of section 301(a) of the Act. We are concerned about the accuracy of the iCare HIV 1&2 Rapid Screen Test product labeling, specifically the statements:

“>99% Sensitivity and >99% Specificity;” and

“Reliable and Fast Results in <15 minutes.”

We are also concerned about the accuracy of the iCare HIV 1&2 Oral Swab Rapid Screen Test product labeling, specifically the statements:

“More than 99.61% sensitivity and 99.8% specificity;” and

“Reliable and Fast Results in <20 minutes.”

Further, both the iCare HIV 1&2 Rapid Screen Test and the iCare HIV 1&2 Oral Swab Rapid Screen Test product labeling include the statement “For Field and Health Care Professional Use;” however, statements on your web site include “A self-diagnostic test for HIV (Human Immuno-deficiency Virus) infection.”

You should take prompt action to correct the violations referenced above. To avoid violating the Act, you must refrain from introducing the iCare HIV 1&2 Rapid Screen Test and the iCare HIV 1&2 Oral Swab Rapid Screen Test into U.S. interstate commerce, and refrain from delivering the products for introduction into U.S. interstate commerce, until premarket approval or an IDE for the devices have been obtained, and your devices otherwise comply fully with the Act.

If you have any questions regarding this matter, you may contact Anna M. Flynn at (240) 402-9156. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration. Please be advised that only written communications are considered official.

Sincerely,

Mary A. Malarkey  
Director  
Office of Compliance and Biologics Quality  
Center for Biologics Evaluation and Research

Cc: Mr. Andre Han  
Vice President, Global Business  
JAL Innovation (Singapore) Pte. Ltd.  
50 Raffles Place  
Level 30  
Singapore Land Tower  
Singapore 048623